Lenvatinib en el tratamiento sistémico de primera línea en Cáncer Diferenciado de Tiroides Refractario a Radioyodo

15 / 27

We’ve the evidence of second line with Lenvatinib
Schlumberger M, et al. N Engl J Med 2015
• 1L PFS vs 2L PFS
Median PFS, months (95% CI)
Lenvatinib 18.7 (16.4–NE)
Placebo 3.6 (2.1–5.3)
HR (95% CI): 0.20 (0.14–0.27)
Log-rank test: P<0.0001
Median PFS, months (95% CI)
Lenvatinib 15.1 (8.8–NE)
Placebo 3.6 (1.9–3.7)
HR (95% CI): 0.22 (0.12–0.41)
Log-rank test: P<0.0001